Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors

Area of Science:

• Neuro-oncology
• Immunology
• Pharmacology

Background:

• Glioblastoma multiforme is an aggressive brain tumor with poor prognosis despite standard treatments.
• Immunotherapy shows promise but is often hindered by immune-suppressive molecules like prostaglandins.
• Cyclooxygenase-2 (COX-2) is implicated in tumor progression and immune suppression.

Purpose of the Study:

• To investigate the combined effect of immunotherapy and COX-2 inhibition on experimental brain tumors.
• To evaluate the efficacy of combining irradiated interferon-gamma (IFN-γ)-secreting tumor cells with parecoxib, a COX-2 inhibitor.
• To explore the impact on survival rates and systemic immune response.

Main Methods:

• Treatment of established rat brain tumors with immunotherapy (irradiated IFN-γ-secreting tumor cells) and/or parecoxib.
• Assessment of long-term survival rates and plasma IFN-γ levels.
• In vivo and in vitro analysis of COX-2 expression and prostaglandin E(2) production by tumor cells.

Main Results:

• Combined therapy significantly enhanced long-term cure rates (81% survival) compared to immunotherapy alone (19% survival).
• The combination therapy led to increased plasma IFN-γ levels, indicating a systemic T helper 1 immune response.
• COX-2 inhibition alone did not improve survival; tumor cells were identified as the primary source of COX-2.

Conclusions:

• Immunotherapy for experimental brain tumors is significantly potentiated by concurrent COX-2 inhibition.
• The findings support the clinical use of parecoxib in combination with immunotherapy for human brain tumors.
• IFN-γ plasma levels can serve as a biomarker for monitoring in vivo immune response, with translational potential.